Company Overview and News


Add HALO
to your dashboard

Headline News

Halozyme Therapeutics, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-10 seekingalpha
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2017 Q3 earnings call. (52-0)

Cramer's lightning round: Cimarex's quarter was 'the best' of the oils

2017-11-08 cnbc
Exxon Mobil Corporation: "Exxon's fine. I prefer Chevron over Exxon if you want the majors. Cimarex reported a quarter today that was the best. Club members of the ActionAlertsPlus.com club know this is my favorite. What a monster quarter." (92-0)

Halozyme Therapeutics' (HALO) CEO Dr. Helen Torley on Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Good afternoon and welcome to the Halozyme Therapeutics Third Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference call is being recorded. (141-0)

Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus

2017-10-26 zacks
Bristol-Myers Squibb Company’s (BMY - Free Report) third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents. (258-0)

Your Daily Pharma Scoop: Everybody's Gilead Problem, Halozyme's Further Progress, Ziopharm's Gene Therapy

2017-10-17 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (305-3)

Halozyme Therapeutics: Updates To Thesis

2017-09-21 seekingalpha
Adoption and utilization of its ENHANZE technology continues to drive growth, highlighted by the recent deal signed with Bristol-Myers Squibb. (124-0)

TrovaGene Strengthens Board Of Directors With Appointment Of Oncology Development Veteran

2017-09-20 devicespace
SAN DIEGO, Sept. 20, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the expansion and strengthening of its Board of Directors with the appointment of Athena Countouriotis, M.D. (69-0)

Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook

2017-09-20 zacks
A key development this week was the FDA approval of the first cancer biosimilar - Amgen (AMGN - Free Report) and Allergan’s Mvasi, a biosimilar version of Roche’s blockbuster cancer drug, Avastin. Other updates include important data presentations from companies like Nabriva Therapeutics (NBRV - Free Report) and AbbVie (ABBV - Free Report) . Recap of the Week’s Most Important Stories First Cancer Biosimilar Gets FDA Nod: The FDA approved Amgen and Allergan’s Mvasi, a biosimilar version of Roche’s blockbuster cancer drug, Avastin (bevacizumab). (305-0)

Faison's Weekend Review And Scans

2017-09-16 seekingalpha
In this weekly series, I present a few ideas from scans for reader discussion and further due diligence. (16-8)

Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?

2017-09-16 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (4-1)

Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today

2017-09-14 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (3-0)

Biotech Forum Daily Digest: Revisiting Radius Health

2017-09-14 seekingalpha
The main biotech indices are down slightly on the week in listless trading as the sector consolidates recent gains. (7-2)

Here's Why Halozyme Therapeutics, Inc. Is Soaring Today

2017-09-14 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (3-0)

Halozyme Inks $2B+ in ENHANZE Licensing Deals with BMS, Roche

2017-09-14 genengnews
Digital Technology and Human Intuition Will Work Together to Derive Clinically Actionable Information from Whole-Slide Scans (3-0)

CUSIP: 40637H109